Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01829256 · ClinicalTrials.gov registry record · NA
Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 285
- Enrollment target
NCT01829256: Completed NA study, sponsored by Duke University.
NCT01829256 is a NA study that has completed, run by Duke University. The registered enrollment target is 285 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01829256, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 285 participants
- Enrollment target
Study Summary
Diabetic kidney disease (DKD) is associated with high rates of cardiovascular events and death. In addition, DKD is the major cause of end-stage renal disease (ESRD) in the United States. The purpose of this study is to prevent progression of kidney disease among patients with DKD and uncontrolled hypertension (HTN) using a tailored, telehealth intervention that simultaneously address medication management and modifies multiple risk factors through a combination of patient self-monitoring, behavioral therapies and education to optimize adherence and self-efficacy. Additional goals are to improve control of cardiovascular disease risk factors and reduce cardiovascular events and death. We hypothesize that patients with DKD and uncontrolled HTN who receive this intervention will have less progression, or a smaller decrease in kidney function, after 3 years when compared to the education control group.
Interventions
- BEHAVIORAL Pharmacist telehealth intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-11-07 |
| Phase | NA |
What the finished NCT01829256 record still lists
NCT01829256 is an interventional study that assigns participants to a tested intervention. The registered 285 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which Pharmacist telehealth intervention is the first listed.
NCT01829256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01829256 about?
NCT01829256 is a clinical study titled "Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)". Diabetic kidney disease (DKD) is associated with high rates of cardiovascular events and death. In addition, DKD is the major cause of end-stage renal disease (ESRD) in the United States. The purpose of this study is to prevent progression of kidney disease among patients with DKD and uncontrolled h...
What is the current status of trial NCT01829256?
This trial is currently completed. It is a NA study. The enrollment target is 285 participants. The study started on 2014-05. Estimated completion is 2018-11-07.
What interventions are being tested in trial NCT01829256?
The interventions under investigation include: Pharmacist telehealth intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT01829256?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01829256's enrollment target sits among peer trials
285 377th of 2000 higher than 1,624 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03412877 · 285 participants · Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- NCT04537936 · 285 participants · NA
Psychotherapy Intervention for Latinos With Adv Cancer
- NCT04965675 · 285 participants · Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- NCT05320835 · 285 participants · NA
A Setting Focus Overdose Prevention Intervention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia